Lymphoproliferative Disorders Clinical Trial
Official title:
Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03663933 -
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
|
Phase 2 | |
| Recruiting |
NCT04339777 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
|
Phase 2 | |
| Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
| Enrolling by invitation |
NCT01728402 -
Pathogenesis of Hematologic Malignancies
|
||
| Completed |
NCT00068146 -
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
|
||
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
| Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 | |
| Recruiting |
NCT02579967 -
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
|
Phase 2 | |
| Recruiting |
NCT05803616 -
Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders
|
||
| Recruiting |
NCT02505789 -
Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients
|
N/A | |
| Withdrawn |
NCT00968461 -
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
|
Phase 1 | |
| Recruiting |
NCT01186224 -
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
|
N/A | |
| Terminated |
NCT00992732 -
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
|
Phase 2 | |
| Completed |
NCT00063648 -
Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant
|
Phase 1 | |
| Terminated |
NCT03601819 -
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
|
Phase 1 | |
| Active, not recruiting |
NCT04309084 -
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04858256 -
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
|
Phase 2 | |
| Completed |
NCT03397706 -
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05431179 -
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 3 |